Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comparative effectiveness: asking the right questions, choosing the right method.

Steven M Teutsch1, Marc L Berger, Milton C Weinstein

  • 1Merck and Company Inc., West Point, Pennsylvania, USA. steven_teutsch@merck.com

Health Affairs (Project Hope)
|January 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Component Clinical and Cost Outcomes Complementing Value of Information: Case Study of a Tuberculosis Diagnostics Clinical Trial.

PharmacoEconomics·2026
Same author

The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study.

The lancet. HIV·2025
Same author

Clinical impact and cost-effectiveness of the WHO-recommended advanced HIV disease package of care.

The Lancet. Global health·2025
Same author

Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens.

PloS one·2025
Same author

Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union.

Bioengineering (Basel, Switzerland)·2024
Same author

When Will Real-World Data Fulfill Its Promise to Provide Timely Insights in Oncology?

JCO clinical cancer informatics·2024
Same journal

National Health Expenditure Projections, 2025-34: Strong Utilization Growth Initially, Legislative Impacts Later.

Health affairs (Project Hope)·2026
Same journal

State Medicaid Programs Face Increased Spending On Medicare Premiums.

Health affairs (Project Hope)·2026
Same journal

Not enough time.

Health affairs (Project Hope)·2026
Same journal

Medicaid Tobacco And Nicotine Cessation Treatment Rates Remained Low, 2019-24.

Health affairs (Project Hope)·2026
Same journal

Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs.

Health affairs (Project Hope)·2026
Same journal

The Opacity Of Price Transparency.

Health affairs (Project Hope)·2026
See all related articles

Assessing therapeutic options requires careful evidence evaluation. This study proposes a framework for choosing appropriate methods based on clear policy goals for Medicare drug decision-making.

Area of Science:

  • Health economics
  • Health services research
  • Pharmaceutical policy

Background:

  • The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 emphasizes comparative effectiveness research.
  • Drug formulary decision-makers often lack complete evidence for therapeutic options.
  • Existing methods like comparative randomized trials and decision-modeling have limitations.

Purpose of the Study:

  • To propose a framework for assessing comparative effectiveness of therapeutic options.
  • To guide the selection of appropriate evidence assessment methods.
  • To align method selection with clear policy goals.

Main Methods:

  • Review of evidence assessment strategies for therapeutic options.
  • Analysis of limitations in comparative randomized trials and decision-modeling.

Related Experiment Videos

  • Development of a framework for choosing assessment methods.

    • Main Results:

    • Comparative randomized trials may miss existing differences.
    • Decision-modeling may identify non-existent differences.
    • A framework is proposed to address these limitations.

    Conclusions:

    • Choosing the right method for assessing therapeutic options is crucial.
    • Clear policy goals are essential for selecting appropriate evidence assessment methods.
    • The proposed framework aims to improve drug formulary decision-making.